JP2003523739A5 - - Google Patents

Download PDF

Info

Publication number
JP2003523739A5
JP2003523739A5 JP2001553387A JP2001553387A JP2003523739A5 JP 2003523739 A5 JP2003523739 A5 JP 2003523739A5 JP 2001553387 A JP2001553387 A JP 2001553387A JP 2001553387 A JP2001553387 A JP 2001553387A JP 2003523739 A5 JP2003523739 A5 JP 2003523739A5
Authority
JP
Japan
Prior art keywords
compound
antisense
seq
ptp1b
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001553387A
Other languages
English (en)
Other versions
JP2003523739A (ja
JP4054192B2 (ja
Filing date
Publication date
Priority claimed from US09/487,368 external-priority patent/US6261840B1/en
Application filed filed Critical
Publication of JP2003523739A publication Critical patent/JP2003523739A/ja
Publication of JP2003523739A5 publication Critical patent/JP2003523739A5/ja
Application granted granted Critical
Publication of JP4054192B2 publication Critical patent/JP4054192B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Description

【特許請求の範囲】
【請求項1】 PTP1Bをコードする核酸分子を標的とする配列番号164−173の1つを含んでなる30核酸塩基長までのアンチセンス化合物であって、PTP1Bに、特異的にハイブリダイズしそして発現を阻害する、上記化合物。
【請求項2】 アンチセンスオリゴヌクレオチドである、請求項1に記載のアンチセンス化合物。
【請求項3】 アンチセンスオリゴヌクレオチドが、配列番号:164、165、166、168、169、170、171、172または173からなる配列を有する、請求項2に記載のアンチセンス化合物。
【請求項4】 アンチセンスオリゴヌクレオチドが少なくとも1つの修飾されたヌクレオシド間結合を含んで成る、請求項2に記載のアンチセンス化合物。
【請求項5】 修飾されたヌクレオシド間結合がホスホロチオエート結合である、請求項4に記載のアンチセンス化合物。
【請求項6】 アンチセンスオリゴヌクレオチドが少なくとも1つの修飾された糖部分を含んで成る、請求項2に記載のアンチセンス化合物。
【請求項7】 修飾された糖部分が2'−O−メトキシエチル糖部分である、請求項6に記載のアンチセンス化合物。
【請求項8】 アンチセンスオリゴヌクレオチドが少なくとも1つの修飾された核酸塩基を含んで成る、請求項2に記載のアンチセンス化合物。
【請求項9】 修飾された核酸塩基が5−メチルシトシンである、請求項8に記載のアンチセンス化合物。
【請求項10】 アンチセンスオリゴヌクレオチドがキメラオリゴヌクレオチドである、請求項2に記載のアンチセンス化合物。
【請求項11】 配列番号166の配列を有する、請求項1に記載のアンチセンス化合物。
【請求項12】 配列番号166のヌクレオチド1−5及び16−20が2'−O−メトキシエチルヌクレオシドであり、ヌクレオチド6−15が2’−デオキシヌクレオチドであり、全てのシチジン残基が5−メチルシチジンであり、そして全てのヌクレオシド間結合がホスホロチオエートである、請求項11に記載のアンチセンス化合物。
【請求項13】 請求項1から12のいずれかに記載のアンチセンス化合物および製薬学的に許容されるキャリアーまたは希釈剤を含んで成る組成物。
【請求項14】 さらにコロイド状分散系を含んで成る、請求項1に記載の組成物。
【請求項15】 医薬として使用するための、請求項1−12に記載の組成物。
【請求項16】 糖尿病、肥満、ガンまたは高増殖性障害を処置するための医薬の製造における請求項1−12に記載の化合物の使用。
【請求項17】 PTP1Bの発現を阻害するように細胞または組織を請求項1−12のいずれかに記載のアンチセンス化合物と接触させることを含んで成る、インビトロで細胞または組織中のPTP1Bの発現を阻害する方法。

Claims (31)

  1. PTP1Bをコードする核酸分子を標的とする8〜30核酸塩基長の化合物であって、PTP1Bに、特異的にハイブリダイズしそして発現を阻害する、上記化合物。
  2. アンチセンスオリゴヌクレオチドである、請求項1に記載の化合物。
  3. アンチセンスオリゴヌクレオチドが、配列番号:18、19、20、21、22、23、24、26、27、29、30、32、33、35、36、38、39、40、42、45、46、47、48、49、50、52、53、54、55、56、57、58、59、60、61、62、63、64、65、66、67、69、70、72、73、75、78、79、80、81、83、84、86、87、89、90、92、93、94、95、96、97、99、100、101、102、103、104、106、107、108、109、110、112、113、114、115、117、120、121、122、123、124、126、127、128、130、131、133、134、135、136、137、138、139、140、141、142、144、145、146、147、148、151、152、153、154、155、156、157、158、159、160、161、162、163、164、165、166、168、169、170、171、172、173、177、178、179、180、181、182、183、184、185、186、187、188、189、191、193、195、196、198、201、202、204、205、206、211、215、217、219、223、225、226、228、229、230、232、233、235、236、237、239または240から成る群から選ばれる配列の少なくとも8核酸塩基部分を含んで成る、請求項2に記載の化合物。
  4. アンチセンスオリゴヌクレオチドが少なくとも1つの修飾されたヌクレオシド間結合を含んで成る、請求項2に記載の化合物。
  5. 修飾されたヌクレオシド間結合がホスホロチオエート結合である、請求項4に記載の化合物。
  6. アンチセンスオリゴヌクレオチドが少なくとも1つの修飾された糖部分を含んで成る、請求項2に記載の化合物。
  7. 修飾された糖部分が2'-O-メトキシエチル糖部分である、請求項6に記載の化合物。
  8. アンチセンスオリゴヌクレオチドが少なくとも1つの修飾された核酸塩基を含んで成る、請求項2に記載の化合物。
  9. 修飾された核酸塩基が5-メチルシトシンである、請求項8に記載の化合物。
  10. アンチセンスオリゴヌクレオチドがキメラオリゴヌクレオチドである、請求項2に記載の化合物。
  11. 請求項1に記載のアンチセンス化合物および製薬学的に許容されるキャリアーまたは希釈剤を含んで成る組成物。
  12. さらにコロイド状分散系を含んで成る、請求項11に記載の組成物。
  13. アンチセンス化合物がアンチセンスオリゴヌクレオチドである、請求項11に記載の組成物。
  14. PTP1Bの発現を阻害するように細胞または組織を請求項1に記載の化合物と接触させることを含んで成る、細胞または組織中のPTP1Bの発現を阻害する方法。
  15. PTP1Bの発現を阻害するように治療的にまたは予防的に有効な量の請求項1に記載のアンチセンス化合物を動物に投与することを含んで成る、PTP1Bに関連する疾患または症状を有する動物を処置する方法。
  16. 疾患または症状が糖尿病である、請求項15に記載の方法。
  17. 疾患または症状が肥満である、請求項15に記載の方法。
  18. 疾患または症状が高増殖性障害である、請求項15に記載の方法。
  19. 高増殖性障害がガンである、請求項15に記載の方法。
  20. 配列番号20から成るアンチセンス化合物。
  21. 配列番号20の少なくとも8核酸塩基部分を含んで成る最高30核酸塩基長の、ヒトPTP1Bの発現を阻害するアンチセンス化合物。
  22. 配列番号166の少なくとも8核酸塩基部分を含んで成る、最高30核酸塩基長の、ヒトPTP1Bの発現を阻害するアンチセンス化合物。
  23. 配列番号166である、請求項22に記載のアンチセンス化合物。
  24. 請求項26に記載のアンチセンス化合物および製薬学的に許容されるキャリアーまたは希釈剤を含んで成る組成物。
  25. 請求項22に記載のアンチセンス化合物およびコロイド状分散系を含んで成る組成物。
  26. 化合物が配列番号166の少なくとも8核酸塩基部分を含んで成る、請求項14に記載の方法。
  27. 化合物が配列番号166である、請求項26に記載の方法。
  28. 化合物が配列番号166の少なくとも8核酸塩基部分を含んで成る、請求項15に記載の方法。
  29. 化合物が配列番号166である、請求項28に記載の方法。
  30. 動物がヒトである、請求項15に記載の方法。
  31. PTP1Bをコードする核酸分子の活性部位の少なくとも8核酸塩基部分と特異的にハイブリダイズする、請求項1に記載の化合物。
JP2001553387A 2000-01-18 2001-01-04 Ptp1b発現のアンチセンス阻害 Expired - Fee Related JP4054192B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/487,368 2000-01-18
US09/487,368 US6261840B1 (en) 2000-01-18 2000-01-18 Antisense modulation of PTP1B expression
PCT/US2001/000109 WO2001053528A1 (en) 2000-01-18 2001-01-04 Antisense inhibition of ptp1b expression

Publications (3)

Publication Number Publication Date
JP2003523739A JP2003523739A (ja) 2003-08-12
JP2003523739A5 true JP2003523739A5 (ja) 2007-02-01
JP4054192B2 JP4054192B2 (ja) 2008-02-27

Family

ID=23935456

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001553387A Expired - Fee Related JP4054192B2 (ja) 2000-01-18 2001-01-04 Ptp1b発現のアンチセンス阻害

Country Status (11)

Country Link
US (1) US6261840B1 (ja)
EP (4) EP2213291A1 (ja)
JP (1) JP4054192B2 (ja)
AT (1) ATE395426T1 (ja)
AU (1) AU2001226246A1 (ja)
CA (1) CA2397590C (ja)
DE (1) DE60133991D1 (ja)
DK (1) DK1250455T3 (ja)
ES (1) ES2307583T3 (ja)
PT (1) PT1250455E (ja)
WO (1) WO2001053528A1 (ja)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6602857B1 (en) 2000-01-18 2003-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
US20020055479A1 (en) * 2000-01-18 2002-05-09 Cowsert Lex M. Antisense modulation of PTP1B expression
US7179796B2 (en) * 2000-01-18 2007-02-20 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
US20070270579A1 (en) * 2001-05-18 2007-11-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20050070497A1 (en) * 2001-05-18 2005-03-31 Sirna Therapeutics, Inc. RNA interference mediated inhibtion of tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)
US20040019001A1 (en) * 2002-02-20 2004-01-29 Mcswiggen James A. RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US20050282188A1 (en) * 2001-05-18 2005-12-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20080161256A1 (en) * 2001-05-18 2008-07-03 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20060241075A1 (en) * 2001-05-18 2006-10-26 Sirna Therapeutics, Inc. RNA interference mediated inhibition of desmoglein gene expression using short interfering nucleic acid (siNA)
US20070042983A1 (en) * 2001-05-18 2007-02-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20060019913A1 (en) * 2001-05-18 2006-01-26 Sirna Therapeutics, Inc. RNA interference mediated inhibtion of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)
US7132529B2 (en) * 2001-07-30 2006-11-07 Isis Pharmaceuticals, Inc. Antisense modulation of stearoyl-CoA desaturase expression
US20050043256A1 (en) * 2001-07-30 2005-02-24 Isis Pharmaceuticals, Inc. Antisense modulation of stearoyl-CoA desaturase expression
US20040191926A1 (en) * 2001-09-26 2004-09-30 Zhong-Yin Zhang Ptp1b inhibitors and ligands
US20090233983A1 (en) * 2002-02-20 2009-09-17 Sirna Therapeutics Inc. RNA Interference Mediated Inhibition of Protein Tyrosine Phosphatase-1B (PTP-1B) Gene Expression Using Short Interfering RNA
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US7897757B2 (en) * 2002-02-20 2011-03-01 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)
AU2003207708A1 (en) * 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2003239897A1 (en) * 2002-05-23 2003-12-12 Ceptyr, Inc. Modulation of ptp1b signal transduction by rna interference
US20040077567A1 (en) * 2002-10-16 2004-04-22 Isis Pharmaceuticals Inc. Antisense modulation of CD36 expression
US20040076621A1 (en) * 2002-10-16 2004-04-22 Isis Pharmaceuticals Inc. Antisense modulation of CD36 expression
ES2566632T3 (es) 2002-11-25 2016-04-14 Masafumi Matsuo Fármacos de ácido nucleico ENA que modifican el corte y empalme en precursores de ARNm
WO2005016862A1 (en) * 2003-08-14 2005-02-24 Asahi Kasei Pharma Corporation Substituted arylalkanoic acid derivative and use thereof
US20050074801A1 (en) * 2003-09-09 2005-04-07 Monia Brett P. Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
CA2582464A1 (en) * 2004-10-13 2006-04-27 Sanjay Bhanot Antisense modulation of ptp1b expression
US20090176725A1 (en) * 2005-08-17 2009-07-09 Sirna Therapeutics Inc. Chemically modified short interfering nucleic acid molecules that mediate rna interference
JP2009536222A (ja) * 2006-05-05 2009-10-08 アイシス ファーマシューティカルズ, インコーポレーテッド Pcsk9の発現を調節するための化合物および方法
EP2215102B1 (en) * 2007-10-01 2016-02-17 Ionis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 4 expression
AU2010211133A1 (en) * 2009-02-03 2011-07-21 F. Hoffmann-La Roche Ag Compositions and methods for inhibiting expression of PTP1B genes
JP6106085B2 (ja) 2010-08-24 2017-03-29 サーナ・セラピューティクス・インコーポレイテッドSirna Therapeutics,Inc. 内部非核酸スペーサーを含む一本鎖RNAi剤
DK2632472T3 (en) 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
EP2697244B1 (en) 2011-04-13 2017-05-17 Ionis Pharmaceuticals, Inc. Antisense modulation of ptp1b expression
WO2014022455A1 (en) * 2012-07-31 2014-02-06 The Board Of Regents Of The University Of Texas System Methods and compositions for in vivo induction of pancreatic beta cell formation
RU2686080C2 (ru) 2013-05-01 2019-04-24 Ионис Фармасьютикалз, Инк. Композиции и способы
KR102149571B1 (ko) 2014-05-01 2020-08-31 아이오니스 파마수티컬즈, 인코포레이티드 성장 호르몬 수용체 발현을 조절하기 위한 조성물 및 방법
US10570169B2 (en) 2014-05-22 2020-02-25 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
KR20190065341A (ko) 2016-10-06 2019-06-11 아이오니스 파마수티컬즈, 인코포레이티드 올리고머 화합물들의 접합 방법
AU2017386771A1 (en) 2016-12-28 2019-06-20 Daiichi Sankyo Company, Limited Therapeutic drug for Alport's syndrome
US11958878B2 (en) 2018-03-09 2024-04-16 Daiichi Sankyo Company, Limited Therapeutic agent for glycogen storage disease type IA
CN112218950A (zh) 2018-06-13 2021-01-12 第一三共株式会社 心肌损伤治疗药
EP3995153A4 (en) 2019-06-26 2023-11-22 KNC Laboratories Co., Ltd. NUCLEIC ACID DRUG SUPPRESSING MYOSTATIN GENE MRNA PRODUCTION
US20220364086A1 (en) 2019-07-12 2022-11-17 Daiichi Sankyo Company, Limited ANTISENSE OLIGONUCLEOTIDE CAPABLE OF ALTERING SPLICING OF DUX4 pre-mRNA
BR112022004461A2 (pt) 2019-09-10 2022-07-19 Daiichi Sankyo Co Ltd Conjugado de galnac-oligonucleotídeo para entrega ao fígado e método de fabricação do mesmo
EP4043473A4 (en) 2019-10-11 2024-03-27 Sumitomo Chemical Company, Limited METHOD FOR PRODUCING NUCLEIC ACID OLIGOMERS
JP2023514503A (ja) 2020-01-29 2023-04-06 住友化学株式会社 核酸オリゴマーの製造方法
JPWO2021153047A1 (ja) 2020-01-29 2021-08-05
WO2021182517A1 (ja) 2020-03-11 2021-09-16 隆光 矢野 -1フレームシフトを誘導するための1本鎖核酸分子及び組成物
US20230167152A1 (en) 2020-03-27 2023-06-01 Sumitomo Chemical Company, Limited Method for producing nucleic acid oligomer
EP4180442A1 (en) 2020-07-09 2023-05-17 Sumitomo Chemical Company, Limited Method for producing nucleic acid oligomer
WO2022024833A1 (ja) 2020-07-28 2022-02-03 神戸天然物化学株式会社 アンギオテンシン変換酵素2遺伝子のエクソンのスキッピングを誘導するアンチセンス核酸
US20240051986A1 (en) 2020-09-24 2024-02-15 Sumitomo Chemical Company, Limited Method for producing nucleic acid oligomer
EP4299743A1 (en) 2021-02-26 2024-01-03 KNC Laboratories Co., Ltd. Nucleic acid medicine expressing splicing variant of myostatin
CN117980285A (zh) 2021-09-28 2024-05-03 住友化学株式会社 纯化二氯乙酸的制造方法
WO2023182274A1 (ja) 2022-03-23 2023-09-28 住友化学株式会社 核酸オリゴマーの製造方法
WO2024089953A1 (ja) 2022-10-27 2024-05-02 住友化学株式会社 オリゴヌクレオチドの製造方法

Family Cites Families (190)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4534899A (en) 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4426330A (en) 1981-07-20 1984-01-17 Lipid Specialties, Inc. Synthetic phospholipid compounds
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US4476301A (en) 1982-04-29 1984-10-09 Centre National De La Recherche Scientifique Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon
JPS5927900A (ja) 1982-08-09 1984-02-14 Wakunaga Seiyaku Kk 固定化オリゴヌクレオチド
FR2540122B1 (fr) 1983-01-27 1985-11-29 Centre Nat Rech Scient Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation, leur procede de synthese et leur application
US4605735A (en) 1983-02-14 1986-08-12 Wakunaga Seiyaku Kabushiki Kaisha Oligonucleotide derivatives
US4948882A (en) 1983-02-22 1990-08-14 Syngene, Inc. Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
US4824941A (en) 1983-03-10 1989-04-25 Julian Gordon Specific antibody to the native form of 2'5'-oligonucleotides, the method of preparation and the use as reagents in immunoassays or for binding 2'5'-oligonucleotides in biological systems
US4587044A (en) 1983-09-01 1986-05-06 The Johns Hopkins University Linkage of proteins to nucleic acids
US5118800A (en) 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
US5118802A (en) 1983-12-20 1992-06-02 California Institute Of Technology DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside
US5550111A (en) 1984-07-11 1996-08-27 Temple University-Of The Commonwealth System Of Higher Education Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
FR2567892B1 (fr) 1984-07-19 1989-02-17 Centre Nat Rech Scient Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons
US5367066A (en) 1984-10-16 1994-11-22 Chiron Corporation Oligonucleotides with selectably cleavable and/or abasic sites
US5430136A (en) 1984-10-16 1995-07-04 Chiron Corporation Oligonucleotides having selectably cleavable and/or abasic sites
US5258506A (en) 1984-10-16 1993-11-02 Chiron Corporation Photolabile reagents for incorporation into oligonucleotide chains
US4828979A (en) 1984-11-08 1989-05-09 Life Technologies, Inc. Nucleotide analogs for nucleic acid labeling and detection
FR2575751B1 (fr) 1985-01-08 1987-04-03 Pasteur Institut Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5405938A (en) 1989-12-20 1995-04-11 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US4762779A (en) 1985-06-13 1988-08-09 Amgen Inc. Compositions and methods for functionalizing nucleic acids
US5317098A (en) 1986-03-17 1994-05-31 Hiroaki Shizuya Non-radioisotope tagging of fragments
JPS638396A (ja) 1986-06-30 1988-01-14 Wakunaga Pharmaceut Co Ltd ポリ標識化オリゴヌクレオチド誘導体
DE3788914T2 (de) 1986-09-08 1994-08-25 Ajinomoto Kk Verbindungen zur Spaltung von RNS an eine spezifische Position, Oligomere, verwendet bei der Herstellung dieser Verbindungen und Ausgangsprodukte für die Synthese dieser Oligomere.
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
JP2828642B2 (ja) 1987-06-24 1998-11-25 ハワード フローレイ インスティテュト オブ イクスペリメンタル フィジオロジー アンド メディシン ヌクレオシド誘導体
US5585481A (en) 1987-09-21 1996-12-17 Gen-Probe Incorporated Linking reagents for nucleotide probes
US5188897A (en) 1987-10-22 1993-02-23 Temple University Of The Commonwealth System Of Higher Education Encapsulated 2',5'-phosphorothioate oligoadenylates
US4924624A (en) 1987-10-22 1990-05-15 Temple University-Of The Commonwealth System Of Higher Education 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
US5525465A (en) 1987-10-28 1996-06-11 Howard Florey Institute Of Experimental Physiology And Medicine Oligonucleotide-polyamide conjugates and methods of production and applications of the same
DE3738460A1 (de) 1987-11-12 1989-05-24 Max Planck Gesellschaft Modifizierte oligonukleotide
US5403711A (en) 1987-11-30 1995-04-04 University Of Iowa Research Foundation Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved
WO1989005358A1 (en) 1987-11-30 1989-06-15 University Of Iowa Research Foundation Dna and rna molecules stabilized by modifications of the 3'-terminal phosphodiester linkage and their use as nucleic acid probes and as therapeutic agents to block the expression of specifically targeted genes
US5082830A (en) 1988-02-26 1992-01-21 Enzo Biochem, Inc. End labeled nucleotide probe
EP0406309A4 (en) 1988-03-25 1992-08-19 The University Of Virginia Alumni Patents Foundation Oligonucleotide n-alkylphosphoramidates
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5109124A (en) 1988-06-01 1992-04-28 Biogen, Inc. Nucleic acid probe linked to a label having a terminal cysteine
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5175273A (en) 1988-07-01 1992-12-29 Genentech, Inc. Nucleic acid intercalating agents
US5262536A (en) 1988-09-15 1993-11-16 E. I. Du Pont De Nemours And Company Reagents for the preparation of 5'-tagged oligonucleotides
GB8824593D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Liposomes
US5512439A (en) 1988-11-21 1996-04-30 Dynal As Oligonucleotide-linked magnetic particles and uses thereof
US5457183A (en) 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
US5599923A (en) 1989-03-06 1997-02-04 Board Of Regents, University Of Tx Texaphyrin metal complexes having improved functionalization
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5391723A (en) 1989-05-31 1995-02-21 Neorx Corporation Oligonucleotide conjugates
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US4958013A (en) 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
US5227170A (en) 1989-06-22 1993-07-13 Vestar, Inc. Encapsulation process
US5451463A (en) 1989-08-28 1995-09-19 Clontech Laboratories, Inc. Non-nucleoside 1,3-diol reagents for labeling synthetic oligonucleotides
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
US5254469A (en) 1989-09-12 1993-10-19 Eastman Kodak Company Oligonucleotide-enzyme conjugate that can be used as a probe in hybridization assays and polymerase chain reaction procedures
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
US5527528A (en) 1989-10-20 1996-06-18 Sequus Pharmaceuticals, Inc. Solid-tumor treatment method
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5356633A (en) 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
US5399676A (en) 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
ATE190981T1 (de) 1989-10-24 2000-04-15 Isis Pharmaceuticals Inc 2'-modifizierte nukleotide
US5264562A (en) 1989-10-24 1993-11-23 Gilead Sciences, Inc. Oligonucleotide analogs with novel linkages
US5292873A (en) 1989-11-29 1994-03-08 The Research Foundation Of State University Of New York Nucleic acids labeled with naphthoquinone probe
US5177198A (en) 1989-11-30 1993-01-05 University Of N.C. At Chapel Hill Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US5130302A (en) 1989-12-20 1992-07-14 Boron Bilogicals, Inc. Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
US5469854A (en) 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5486603A (en) 1990-01-08 1996-01-23 Gilead Sciences, Inc. Oligonucleotide having enhanced binding affinity
US5670633A (en) 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5587470A (en) 1990-01-11 1996-12-24 Isis Pharmaceuticals, Inc. 3-deazapurines
US5623065A (en) 1990-08-13 1997-04-22 Isis Pharmaceuticals, Inc. Gapped 2' modified oligonucleotides
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5646265A (en) 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5506351A (en) 1992-07-23 1996-04-09 Isis Pharmaceuticals Process for the preparation of 2'-O-alkyl guanosine and related compounds
US5578718A (en) 1990-01-11 1996-11-26 Isis Pharmaceuticals, Inc. Thiol-derivatized nucleosides
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
US5220007A (en) 1990-02-15 1993-06-15 The Worcester Foundation For Experimental Biology Method of site-specific alteration of RNA and production of encoded polypeptides
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
AU7579991A (en) 1990-02-20 1991-09-18 Gilead Sciences, Inc. Pseudonucleosides and pseudonucleotides and their polymers
US5214136A (en) 1990-02-20 1993-05-25 Gilead Sciences, Inc. Anthraquinone-derivatives oligonucleotides
US5321131A (en) 1990-03-08 1994-06-14 Hybridon, Inc. Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
US5470967A (en) 1990-04-10 1995-11-28 The Dupont Merck Pharmaceutical Company Oligonucleotide analogs with sulfamate linkages
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5665710A (en) 1990-04-30 1997-09-09 Georgetown University Method of making liposomal oligodeoxynucleotide compositions
GB9009980D0 (en) 1990-05-03 1990-06-27 Amersham Int Plc Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides
EP0455905B1 (en) 1990-05-11 1998-06-17 Microprobe Corporation Dipsticks for nucleic acid hybridization assays and methods for covalently immobilizing oligonucleotides
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
US5618704A (en) 1990-07-27 1997-04-08 Isis Pharmacueticals, Inc. Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
US5688941A (en) 1990-07-27 1997-11-18 Isis Pharmaceuticals, Inc. Methods of making conjugated 4' desmethyl nucleoside analog compounds
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
DE69126530T2 (de) 1990-07-27 1998-02-05 Isis Pharmaceutical, Inc., Carlsbad, Calif. Nuklease resistente, pyrimidin modifizierte oligonukleotide, die die gen-expression detektieren und modulieren
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5138045A (en) 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5541307A (en) 1990-07-27 1996-07-30 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs and solid phase synthesis thereof
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5623070A (en) 1990-07-27 1997-04-22 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5677437A (en) 1990-07-27 1997-10-14 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5223618A (en) 1990-08-13 1993-06-29 Isis Pharmaceuticals, Inc. 4'-desmethyl nucleoside analog compounds
US5386023A (en) 1990-07-27 1995-01-31 Isis Pharmaceuticals Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
US5218105A (en) 1990-07-27 1993-06-08 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5245022A (en) 1990-08-03 1993-09-14 Sterling Drug, Inc. Exonuclease resistant terminally substituted oligonucleotides
PT98562B (pt) 1990-08-03 1999-01-29 Sanofi Sa Processo para a preparacao de composicoes que compreendem sequencias de nucleo-sidos com cerca de 6 a cerca de 200 bases resistentes a nucleases
US5177196A (en) 1990-08-16 1993-01-05 Microprobe Corporation Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof
US5512667A (en) 1990-08-28 1996-04-30 Reed; Michael W. Trifunctional intermediates for preparing 3'-tailed oligonucleotides
US5214134A (en) 1990-09-12 1993-05-25 Sterling Winthrop Inc. Process of linking nucleosides with a siloxane bridge
US5561225A (en) 1990-09-19 1996-10-01 Southern Research Institute Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages
EP0549686A4 (en) 1990-09-20 1995-01-18 Gilead Sciences Inc Modified internucleoside linkages
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
DE69132510T2 (de) 1990-11-08 2001-05-03 Hybridon, Inc. Verbindung von mehrfachreportergruppen auf synthetischen oligonukleotiden
JP3220180B2 (ja) 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5371241A (en) 1991-07-19 1994-12-06 Pharmacia P-L Biochemicals Inc. Fluorescein labelled phosphoramidites
US5571799A (en) 1991-08-12 1996-11-05 Basco, Ltd. (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5521291A (en) 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
DE59208572D1 (de) 1991-10-17 1997-07-10 Ciba Geigy Ag Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte
US5594121A (en) 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US5484908A (en) 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
US5359044A (en) 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
US5700922A (en) 1991-12-24 1997-12-23 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
US5595726A (en) 1992-01-21 1997-01-21 Pharmacyclics, Inc. Chromophore probe for detection of nucleic acid
US5565552A (en) 1992-01-21 1996-10-15 Pharmacyclics, Inc. Method of expanded porphyrin-oligonucleotide conjugate synthesis
FR2687679B1 (fr) 1992-02-05 1994-10-28 Centre Nat Rech Scient Oligothionucleotides.
US5633360A (en) 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
FR2692265B1 (fr) 1992-05-25 1996-11-08 Centre Nat Rech Scient Composes biologiquement actifs de type phosphotriesters.
US5434257A (en) 1992-06-01 1995-07-18 Gilead Sciences, Inc. Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
AU4413993A (en) 1992-06-30 1994-01-24 Velke, Willi H. Tennis racquet having a surface structure adapted for the reduction of air resistance
EP0577558A2 (de) 1992-07-01 1994-01-05 Ciba-Geigy Ag Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte
US5272250A (en) 1992-07-10 1993-12-21 Spielvogel Bernard F Boronated phosphoramidate compounds
US5652355A (en) 1992-07-23 1997-07-29 Worcester Foundation For Experimental Biology Hybrid oligonucleotide phosphorothioates
DE69333842T2 (de) 1992-07-23 2006-04-27 Isis Pharmaceuticals, Inc., Carlsbad Neue 2'-O-Alkyl-Nukleoside und -Phosphoramidite, Verfahren zu ihrer Herstellung und ihre Verwendungen
ATE162198T1 (de) 1992-07-27 1998-01-15 Hybridon Inc Oligonukleotid alkylphosphonothiate
US5583020A (en) 1992-11-24 1996-12-10 Ribozyme Pharmaceuticals, Inc. Permeability enhancers for negatively charged polynucleotides
US5574142A (en) 1992-12-15 1996-11-12 Microprobe Corporation Peptide linkers for improved oligonucleotide delivery
JP3351476B2 (ja) 1993-01-22 2002-11-25 三菱化学株式会社 リン脂質誘導体及びそれを含有するリポソーム
EP0677056B1 (en) 1993-01-25 1996-05-22 HYBRIDON, Inc. Oligonucleotide alkylphosphonates and alkylphosphonothioates
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
EP0685234B1 (en) 1993-02-19 2000-05-10 Nippon Shinyaku Company, Limited Drug composition containing nucleic acid copolymer
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
GB9304618D0 (en) 1993-03-06 1993-04-21 Ciba Geigy Ag Chemical compounds
GB9304620D0 (en) 1993-03-06 1993-04-21 Ciba Geigy Ag Compounds
AU6449394A (en) 1993-03-30 1994-10-24 Sterling Winthrop Inc. Acyclic nucleoside analogs and oligonucleotide sequences containing them
CA2159629A1 (en) 1993-03-31 1994-10-13 Sanofi Oligonucleotides with amide linkages replacing phosphodiester linkages
DE4311944A1 (de) 1993-04-10 1994-10-13 Degussa Umhüllte Natriumpercarbonatpartikel, Verfahren zu deren Herstellung und sie enthaltende Wasch-, Reinigungs- und Bleichmittelzusammensetzungen
US5462854A (en) 1993-04-19 1995-10-31 Beckman Instruments, Inc. Inverse linkage oligonucleotides for chemical and enzymatic processes
FR2705099B1 (fr) 1993-05-12 1995-08-04 Centre Nat Rech Scient Oligonucléotides phosphorothioates triesters et procédé de préparation.
US5534259A (en) 1993-07-08 1996-07-09 Liposome Technology, Inc. Polymer compound and coated particle composition
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5417978A (en) 1993-07-29 1995-05-23 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
US5502177A (en) 1993-09-17 1996-03-26 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
CA2137297C (en) 1993-12-06 2000-04-18 Tsuyoshi Miyazaki Reactive vesicle and functional substance-fixed vesicle
US5457187A (en) 1993-12-08 1995-10-10 Board Of Regents University Of Nebraska Oligonucleotides containing 5-fluorouracil
US5446137B1 (en) 1993-12-09 1998-10-06 Behringwerke Ag Oligonucleotides containing 4'-substituted nucleotides
EP0733059B1 (en) 1993-12-09 2000-09-13 Thomas Jefferson University Compounds and methods for site-directed mutations in eukaryotic cells
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5627053A (en) 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
US5625050A (en) 1994-03-31 1997-04-29 Amgen Inc. Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5597696A (en) 1994-07-18 1997-01-28 Becton Dickinson And Company Covalent cyanine dye oligonucleotide conjugates
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US5580731A (en) 1994-08-25 1996-12-03 Chiron Corporation N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5591721A (en) 1994-10-25 1997-01-07 Hybridon, Inc. Method of down-regulating gene expression
US5512295A (en) 1994-11-10 1996-04-30 The Board Of Trustees Of The Leland Stanford Junior University Synthetic liposomes for enhanced uptake and delivery
US5756122A (en) 1995-06-07 1998-05-26 Georgetown University Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells
EP0843555B1 (en) 1995-08-01 2003-08-27 Isis Pharmaceuticals, Inc. Liposomal oligonucleotide compositions
US5652356A (en) 1995-08-17 1997-07-29 Hybridon, Inc. Inverted chimeric and hybrid oligonucleotides
US5858397A (en) 1995-10-11 1999-01-12 University Of British Columbia Liposomal formulations of mitoxantrone
US5994316A (en) 1996-02-21 1999-11-30 The Immune Response Corporation Method of preparing polynucleotide-carrier complexes for delivery to cells
US5726027A (en) * 1996-03-08 1998-03-10 The Regents Of The University Of California Method for treatment of insulin resistance
US6602857B1 (en) * 2000-01-18 2003-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
WO2002059137A1 (en) * 2000-11-03 2002-08-01 Isis Pharmaceuticals, Inc. Nuclease-based method for detecting and quantitating oligonucleotides

Similar Documents

Publication Publication Date Title
JP2003523739A5 (ja)
US11981897B2 (en) Compounds and methods for modulation of dystrophia myotonica-protein kinase (DMPK) expression
JP6704439B2 (ja) ハンチンチン発現の修飾
CA2397590A1 (en) Antisense inhibition of ptp1b expression
JP2018150344A5 (ja)
JP2004509619A5 (ja)
JP2004513626A5 (ja)
JP2024009262A (ja) Lpaの遺伝子発現の阻害のための組成物及び方法
RU2501803C2 (ru) Композиции и способы модуляции экспрессии рецептора фактора роста фибробластов 4 (fgfr4)
TW201922264A (zh) 用於抑制類血管生成素蛋白-3(ANGPTL3)表現的RNAi藥劑及組合物及使用方法
CA2451643A1 (en) Antisense modulation of superoxide dismutase 1, soluble expression
JP2012050438A5 (ja)
JP2004535179A5 (ja)
JP2009508527A5 (ja)
JP2005503142A5 (ja)
CA2343102A1 (en) Antisense modulation of survivin expression
JP2021527437A (ja) Scn9a発現を調節するためのオリゴヌクレオチド
JP2002543215A (ja) A−dna型およびb−dna型立体配座幾何学形状を有するオリゴヌクレオチド
JP2008523157A5 (ja)
JP2010539950A5 (ja)
JP2016513976A5 (ja)
JP2022514657A (ja) Hsd17b13発現のモジュレータ
US20110172296A1 (en) Modulation of transforming growth factor-beta 1 expression
CA2389036A1 (en) Antisense modulation of integrin-linked kinase expression
JP2005504522A5 (ja)